{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:56:50Z","timestamp":1788955010769,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Multiple myeloma (MM) is considered an incurable hematological neoplasm. For transplant-eligible patients, initial treatment includes an induction phase followed by an autologous stem cell transplantation (ASCT). Despite the introduction of several drugs in the past years, relapses still occur. Nevertheless, some patients achieve sustained responses after successful induction treatment and ASCT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively evaluated all patients diagnosed with MM in our institution who underwent induction treatment and ASCT between 1990 and 2015. The subset of patients who achieved a sustained response (any degree) for 5 or more years after ASCT without further treatment or signs of progression were distinguished as \u201clong-term responders\u201d (LTRs). In the non-LTR group, a cohort referred to as \u201cprolonged responders\u201d (PLRs) showed sustained response of at least 5 years after ASCT but eventually relapsed. We collected and analyzed clinical and laboratory data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two hundred and fifty patients were diagnosed with MM and received induction treatment and ASCT at our institution in the study period. Among them, 54 (21.6%) patients met the criteria for LTR. Some diagnostic features such as a younger age, female gender, ECOG performance status of 0, lower International Staging System (ISS) stage, lower bone marrow plasma cell infiltration, and lower serum levels of calcium, C-reactive protein, and lactate dehydrogenase (LDH) were found to be more prevalent in LTR. Female gender, an ECOG performance status of 0, a localized Durie-Salmon stage, an ISS of I\u2013II, the absence of bone disease, and an LDH within normal range were also predictive of longer progression-free survival (PFS) and overall survival (OS) in the whole cohort. The depth of the response achieved after induction and ASCT as well as the administration of an IMID-based maintenance regimen may play a role in the differences observed on PFS between cohorts. A detectable M-protein with a monoclonal gammopathy of undetermined significance (MGUS)-like behavior was detected in one-third of LTR after ASCT. Although relapses continue to occur in patients who achieve a 5-year treatment-free period after ASCT, a plateau is observed in the survival curves at approximately 21 years of follow-up.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.936993","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T04:53:15Z","timestamp":1656996795000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma"],"prefix":"10.3389","volume":"12","author":[{"given":"Aina","family":"Oliver-Caldes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Soler-Perromat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Mozas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Garrote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Setoain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ignacio","family":"Ar\u00f3stegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Yag\u00fce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Tovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Gerardo","family":"Rodr\u00edguez-Lobato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Teresa","family":"Cibeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fern\u00e1ndez de Larrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct0805626","article-title":"Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma","volume":"360","author":"Harousseau","year":"2009","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867","article-title":"Clinical Course of Patients With Relapsed Multiple Myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clinic Proc"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17888","article-title":"Real-World Data on Survival Improvement in Patients With Multiple Myeloma Treated at a Single Institution Over a 45-Year Period","volume":"196","author":"Rodr\u00edguez-Lobato","year":"2022","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04060-z","article-title":"Long PFS of More Than 7 Years is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents: A Single-Center Experience Over 20-Year Period","volume":"99","author":"Terpos","year":"2020","journal-title":"Ann Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.11.009","article-title":"Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs","volume":"14","author":"Martino","year":"2014","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.9721","article-title":"Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival","volume":"26","author":"Lahuerta","year":"2008","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-332320","article-title":"Long-Term Prognostic Significance of Response in Multiple Myeloma After Stem Cell Transplantation","volume":"118","author":"Martinez-Lopez","year":"2011","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1283","article-title":"Analysis of Long-Term Survival in Multiple Myeloma After First-Line Autologous Stem Cell Transplantation: Impact of Clinical Risk Factors and Sustained Response","volume":"7","author":"Lehners","year":"2018","journal-title":"Cancer Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and Maintenance Therapy With Lenalidomide, Bortezomib and Dexamethasone (RVD) in High-Risk Myeloma Patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00386","article-title":"Standardization of 18F-FDG\u2013PET\/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma","volume":"39","author":"Zamagni","year":"2020","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the Diagnosis and Management of Multiple Myeloma and Other Plasma Cell Disorders: A Consensus Statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.622501","article-title":"PET\/CT in Multiple Myeloma: Beyond FDG","volume":"10","author":"Matteucci","year":"2021","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.084350","article-title":"Natural History and Prognostic Impact of Oligoclonal Humoral Response in Patients With Multiple Myeloma After Autologous Stem Cell Transplantation: Long-Term Results From a Single Institution","volume":"98","author":"Tovar","year":"2013","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.111104","article-title":"Secondary Monoclonal Gammopathy of Undetermined Significance After Allogeneic Stem Cell Transplantation in Multiple Myeloma","volume":"99","author":"Schmitz","year":"2014","journal-title":"Haematologica"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/00220973.1995.9943797","article-title":"Multiple Regression Approach to Analyzing Contingency Tables: Post Hoc and Planned Comparison Procedures","volume":"64","author":"Beasley","year":"1995","journal-title":"J Exp Educ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41408-020-00353-8","article-title":"Characteristics of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma","volume":"10","author":"Paquin","year":"2020","journal-title":"Blood Cancer J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group Molecular Classification of Multiple Myeloma: Spotlight Review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple Myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA\/GEM Clinical Trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-Expression Signature of Benign Monoclonal Gammopathy Evident in Multiple Myeloma is Linked to Good Prognosis","volume":"109","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1053\/j.semnuclmed.2014.08.002","article-title":"Multiple Myeloma: 18f-FDG-PET\/CT and Diagnostic Imaging","volume":"45","author":"Mihailovic","year":"2015","journal-title":"Semin Nucl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e318266cee2","article-title":"The Value of 18F-FDG PET\/CT After Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM): Experience With 77 Patients","volume":"38","author":"Nanni","year":"2013","journal-title":"Clin Nucl Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-Fluorodeoxyglucose Positron Emission Tomography in the Context of Other Imaging Techniques and Prognostic Factors in Multiple Myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic Relevance of 18-F FDG PET\/CT in Newly Diagnosed Multiple Myeloma Patients Treated With Up-Front Autologous Transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.2967\/jnumed.108.056713","article-title":"Relationship Between Cancer Type and Impact of PET and PET\/CT on Intended Management: Findings of the National Oncologic PET Registry","volume":"49","author":"Hillner","year":"2008","journal-title":"J Nucl Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3324\/haematol.2012.067272","article-title":"Analysis of the Immune System of Multiple Myeloma Patients Achieving Long-Term Disease Control by Multidimensional Flow Cytometry","volume":"98","author":"Pessoa de Magalh\u00e3es","year":"2013","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.620596","article-title":"Treg and Oligoclonal Expansion of Terminal Effector CD8+ T Cell as Key Players in Multiple Myeloma","volume":"12","author":"Joshua","year":"2021","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.34","article-title":"Long-Term Survival in Multiple Myeloma is Associated With a Distinct Immunological Profile, Which Includes Proliferative Cytotoxic T-Cell Clones and a Favourable Treg\/Th17 Balance","volume":"3","author":"Bryant","year":"2013","journal-title":"Blood Cancer J"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.936993\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T04:53:17Z","timestamp":1656996797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.936993\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":33,"alternative-id":["10.3389\/fonc.2022.936993"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.936993","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,5]]},"article-number":"936993"}}